SEC Form 4 · accession 0001193125-26-349351
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven Gannon
Director
Period of report
Aug 11, 2026
Accepted (ET)
Aug 13, 2026 · 4:33 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Aug 11, 2026 | S | 10,000 | $64.055 | D | 1,870 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $64.0517 to $64.078, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.